QTc interval. Avoid or Use Alternate Drug.oliceridineMonitor Closely (2)fluvoxamine will increase the level or effect of oliceridine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. fluvoxamine, oliceridine. Either increases toxicity of the other by serotonin levels. Modify Therapy/Monitor Closely.olopatadine intranasalSerious - Use Alternative (1)fluvoxamine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. omaveloxoloneSerious - Use Alternative (1)fluvoxamine will increase the level or effect of omaveloxolone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unavoidable, reduce omaveloxolone dose to 100 mg/day. Closely monitor for adverse effects. If adverse effects emerge, further reduce to 50 mg/day. omeprazoleSerious - Use Alternative (1)fluvoxamine will increase the level or effect of omeprazole by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug.ondansetronSerious - Use Alternative (1)fluvoxamine and ondansetron both increase serotonin levels. Avoid or Use Alternate Drug.ospemifeneMonitor Closely (1)fluvoxamine will increase the level or effect of ospemifene by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.oxaliplatinSerious - Use Alternative (1)oxaliplatin and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.oxaprozinMonitor Closely (1)fluvoxamine, oxaprozin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.oxycodoneMonitor Closely (1)fluvoxamine and oxycodone both increase serotonin levels. Use Caution/Monitor.ozanimodSerious - Use Alternative (1)ozanimod increases toxicity of fluvoxamine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because active metabolite of ozanimod inhibits MAO-B in vitro, there is potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use. .pacritinibSerious - Use Alternative (1)fluvoxamine will increase the level or effect of pacritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.paliperidoneMonitor Closely (1)fluvoxamine and paliperidone both increase QTc interval. Use Caution/Monitor.palonosetronSerious - Use Alternative (1)fluvoxamine and palonosetron both increase serotonin levels. Avoid or Use Alternate Drug.pantoprazoleMonitor Closely (1)fluvoxamine will increase the level or effect of pantoprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.parecoxibMonitor Closely (1)fluvoxamine will increase the level or effect of parecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by plateletsparoxetineMonitor Closely (1)fluvoxamine and paroxetine both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)fluvoxamine and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.pazopanibSerious - Use Alternative (1)fluvoxamine will increase the level or effect of pazopanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If it must be coadminister, decrease pazotinib dose to 400 mg/daypeginterferon alfa 2bMonitor Closely (1)fluvoxamine, peginterferon alfa 2b. Other (see comment). Use Caution/Monitor. Comment: Therapeutic effect may be altered with coadministration of CYP2D6 substrates; peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.pentamidineSerious - Use Alternative (1)fluvoxamine and pentamidine both increase QTc interval. Avoid or Use Alternate Drug.pentazocineMonitor Closely (1)fluvoxamine and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely.pentoxifyllineMonitor Closely (1)fluvoxamine and pentoxifylline both increase anticoagulation. Use Caution/Monitor. may increase bleedingperphenazineMonitor Closely (1)fluvoxamine and perphenazine both increase QTc interval. Use Caution/Monitor.pexidartinibSerious - Use Alternative (1)fluvoxamine will increase the level or effect of pexidartinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong or moderate CYP3A4 inhibitors is unavoidable, reduce pexidartinib dose (refer to drug monograph dosage modifications). After discontinuing the CYP3A4 inhibitor for 3 elimination half-lives, may resume previous pexidartinib dose.phenelzineSerious - Use Alternative (1)fluvoxamine and phenelzine both increase serotonin levels. Contraindicated.phentermineSerious - Use Alternative (1)fluvoxamine and phentermine both increase serotonin levels. Avoid or Use Alternate Drug.phenytoinMonitor Closely (1)fluvoxamine will increase the level or effect of phenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.pimozideSerious - Use Alternative (2)fluvoxamine increases toxicity of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. fluvoxamine and pimozide both increase QTc interval. Avoid or Use Alternate Drug.pirfenidoneSerious - Use Alternative (1)fluvoxamine will increase the level or effect of pirfenidone by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating treatment and avoided during treatment; if strong CYP1A2 inhibitor is only option, dosage reduction recommendedpiroxicamMonitor Closely (1)fluvoxamine, piroxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.pomalidomideSerious - Use Alternative (1)fluvoxamine will increase the level or effect of pomalidomide by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.posaconazoleMonitor Closely (1)fluvoxamine and posaconazole both increase QTc interval. Use Caution/Monitor.pregabalinMonitor Closely (1)fluvoxamine, pregabalin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration may result in life-threatening, and fatal respiratory depression; use lowest dose possible and monitor for respiratory depression and sedation.primaquineMonitor Closely (1)primaquine and fluvoxamine both increase QTc interval. Use Caution/Monitor.procainamideSerious - Use Alternative (1)fluvoxamine and procainamide both increase QTc interval. Avoid or Use Alternate Drug.procarbazineSerious - Use Alternative (1)fluvoxamine and procarbazine both increase serotonin levels. Contraindicated.prochlorperazineMonitor Closely (1)fluvoxamine and prochlorperazine both increase QTc interval. Use Caution/Monitor.promazineMonitor Closely (1)fluvoxamine and promazine both increase QTc interval. Modify Therapy/Monitor Closely.promethazineMonitor Closely (1)fluvoxamine and promethazine both increase QTc interval. Use Caution/Monitor.propafenoneMonitor Closely (1)fluvoxamine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.propofolMonitor Closely (1)fluvoxamine will increase the level or effect of propofol by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.protriptylineMonitor Closely (1)fluvoxamine and protriptyline both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluvoxamine and protriptyline both increase serotonin levels. Avoid or Use Alternate Drug.quetiapineMonitor Closely (1)fluvoxamine will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.quinidineMonitor Closely (1)quinidine will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)fluvoxamine and quinidine both increase QTc interval. Avoid or Use Alternate Drug.rabeprazoleMonitor Closely (1)fluvoxamine will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.ramelteonContraindicated (1)fluvoxamine will increase the level or effect of ramelteon by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated.Monitor Closely (1)fluvoxamine will increase the level or effect of ramelteon by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.ranolazineMonitor Closely (1)fluvoxamine and ranolazine both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)fluvoxamine will increase the level or effect of ranolazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.rasagilineSerious - Use Alternative (1)fluvoxamine and rasagiline both increase serotonin levels. Avoid or Use Alternate Drug. Severe CNS toxicity associated with hyperpyrexia reported with combined treatment of antidepressant and rasagiline; avoid combination within 14 days of MAOI useremifentanilSerious - Use Alternative (1)fluvoxamine and remifentanil both increase serotonin levels. Avoid or Use Alternate Drug.remimazolamMonitor Closely (1)remimazolam, fluvoxamine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.repaglinideMonitor Closely (1)fluvoxamine will increase the level or effect of repaglinide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.riluzoleMonitor Closely (1)fluvoxamine will increase the level or effect of riluzole by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.rimegepantMonitor Closely (1)fluvoxamine will increase the level or effect of rimegepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid repeating dose within 48 hr if coadministered with moderate CYP3A4risperidoneMonitor Closely (1)fluvoxamine and risperidone both increase QTc interval. Use Caution/Monitor.ritlecitinibMonitor Closely (1)ritlecitinib will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Ritlecitinib inhibits CYP1A2 substrates; coadministration increases AUC and peak plasma concentration sensitive substrates, which may increase risk of adverse reactions. Additional monitoring and dosage adjustment may be needed in accordance with product labeling of CYP1A2 substrates. ritonavirMonitor Closely (1)fluvoxamine will increase the level or effect of ritonavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rivaroxabanMonitor Closely (1)fluvoxamine will increase the level or effect of rivaroxaban by pharmacodynamic synergism. Use Caution/Monitor. May increase risk of bleedingrizatriptanMonitor Closely (1)fluvoxamine and rizatriptan both increase serotonin levels. Modify Therapy/Monitor Closely.roflumilastMonitor Closely (1)fluvoxamine increases levels of roflumilast by Other (see comment). Modify Therapy/Monitor Closely. Comment: coadministration with dual inhibitors of CYP3A4 and CYP1A2 may increase systemic exposure and result in increased adverse reactions.rolapitantMonitor Closely (1)rolapitant will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase serum concentrations of CYP2D6 substrates for at least 28 days following rolapitant administrationromidepsinMonitor Closely (1)fluvoxamine and romidepsin both increase QTc interval. Use Caution/Monitor.ropiniroleSerious - Use Alternative (1)fluvoxamine will increase the level or effect of ropinirole by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.rucaparibMonitor Closely (1)rucaparib will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP1A2 substrates, if clinically indicated.safinamideMonitor Closely (1)fluvoxamine, safinamide. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Monitor for serotonin syndrome.salicylates (non-asa)Monitor Closely (1)fluvoxamine, salicylates (non-asa). Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.salsalateMonitor Closely (1)fluvoxamine, salsalate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.SAMeMonitor Closely (1)fluvoxamine and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.saquinavirMonitor Closely (1)fluvoxamine will increase the level or effect of saquinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.selegilineContraindicated (1)fluvoxamine will increase the level or effect of selegiline by affecting hepatic enzyme CYP2B6 metabolism. Contraindicated.Serious - Use Alternative (1)fluvoxamine and selegiline both increase serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of either drug and initiation of the other oneselegiline transdermalSerious - Use Alternative (1)fluvoxamine and selegiline transdermal both increase serotonin levels. Avoid or Use Alternate Drug.selinexorSerious - Use Alternative (1)selinexor, fluvoxamine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sertralineSerious - Use Alternative (2)fluvoxamine and sertraline both increase serotonin levels. Avoid or Use Alternate Drug. sertraline and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.sevofluraneSerious - Use Alternative (1)sevoflurane and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.silodosinMonitor Closely (1)fluvoxamine will increase the level or effect of silodosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.siponimodSerious - Use Alternative (2)fluvoxamine will increase the level or effect of siponimod by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with a moderate or strong CYP3A4 inhibitor PLUS a moderate or strong CYP2C9 inhibitor not recommended siponimod and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.sodium sulfate/?magnesium sulfate/potassium chlorideMonitor Closely (1)sodium sulfate/?magnesium sulfate/potassium chloride increases effects of fluvoxamine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using bowel preps together with drugs that lower the seizure threshold.sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycolMonitor Closely (1)fluvoxamine, sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. Comment: Increased risk for water retention or electrolyte imbalance.sodium sulfate/potassium sulfate/magnesium sulfateMonitor Closely (1)sodium sulfate/potassium sulfate/magnesium sulfate increases effects of fluvoxamine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using bowel preps together with drugs that lower the seizure threshold.sofosbuvir/velpatasvirMonitor Closely (1)fluvoxamine will increase the level or effect of sofosbuvir/velpatasvir by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.solifenacinMonitor Closely (2)fluvoxamine will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. solifenacin and fluvoxamine both increase QTc interval. Use Caution/Monitor.somapacitanMonitor Closely (1)somapacitan will decrease the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Limited published data indicate that growth hormone treatment increases cytochrome P450 (CYP450)-mediated antipyrine clearance. Caution with sensitive CYP substratessomatrogonMonitor Closely (1)somatrogon will decrease the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Limited published data indicate that growth hormone treatment increases cytochrome P450 (CYP450)-mediated antipyrine clearance. Caution with sensitive CYP substratessomatropinMonitor Closely (1)somatropin will decrease the level or effect of fluvoxamine by affecting hepatic enzyme